GoAI
Get started
Ridgetech, Inc. logo

Ridgetech, Inc.

RDGT

NASDAQHealthcareMedical - Distribution

Open in GoAI

Previous close

$0.81

+$0.0043 · +0.53%

Aug 21, 4:00 PM ET

RDGT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

71

Undervalued

Momentum

31

Weakening

Sentiment

61

Bullish

Risk resilience

37

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Ridgetech, Inc. operates as a wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China. It operates through three segments: Retail Drugstores, Online Pharmacy, and Drug Wholesale. The company engages in offline and online wholesale distribution of pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, and medical devices, as well as convenience products comprising consumable, seasonal, and promotional items. It also distributes other healthcare products, such as health food, cosmetics, and daily necessities. The company was formerly known as China Jo-Jo Drugstores, Inc. and changed its name to Ridgetech, Inc. in February 2024. Ridgetech, Inc. is headquartered in Hangzhou, China.

Industry
Medical - Distribution
Sector
Healthcare
Headquarters
CN
CEO
Ming Zhao
Listed since
Oct 1, 2009
Employees
64

Market position

Day range

Current $0.81

52-week range

Current $0.81

Open
$0.7895
Previous close
$0.8057
Volume
64.69K
0.02× average
Average volume
2.97M
Average daily volume
Market cap
728.12K USD
Beta
-0.19
Market reference 1
50-day average
$1.2314
-34.22% below average
200-day average
$194.2
-99.58% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-17.54M USD
EV / EBITDA
11.67×
Earnings yield
-351.91%
Free cash flow yield
-392.42%

Profitability & efficiency

Return on equity
-3.07%
Return on assets
-1.81%
Return on invested capital
-4.20%

Financial health

Current ratio
2.31×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends27%12%-3%-18%Gross margin, FY2022: 22.21%Gross margin, FY2023: 23.04%Gross margin, FY2024: 20.13%Gross margin, FY2025: 3.20%Gross margin, FY2026: 3.60%Operating margin, FY2022: -1.64%Operating margin, FY2023: -14.06%Operating margin, FY2024: -2.29%Operating margin, FY2025: -0.86%Operating margin, FY2026: -1.41%Net margin, FY2022: -1.94%Net margin, FY2023: -14.20%Net margin, FY2024: -2.74%Net margin, FY2025: 8.50%Net margin, FY2026: -0.95%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 22.21%. Gross margin FY2023 23.04%. Gross margin FY2024 20.13%. Gross margin FY2025 3.20%. Gross margin FY2026 3.60%. Operating margin FY2022 -1.64%. Operating margin FY2023 -14.06%. Operating margin FY2024 -2.29%. Operating margin FY2025 -0.86%. Operating margin FY2026 -1.41%. Net margin FY2022 -1.94%. Net margin FY2023 -14.20%. Net margin FY2024 -2.74%. Net margin FY2025 8.50%. Net margin FY2026 -0.95%.

Income trends

Revenue

132.16M USD+10.16%

Operating income

−1.87M USD-80.23%

Net income

−1.25M USD−11.44M USD
Income trends across reported periods182.95M USD108.73M USD34.52M USD−39.69M USDRevenue, FY2022: 164.39M USDRevenue, FY2023: 148.81M USDRevenue, FY2024: 154.54M USDRevenue, FY2025: 119.97M USDRevenue, FY2026: 132.16M USDOperating income, FY2022: −2.69M USDOperating income, FY2023: −20.93M USDOperating income, FY2024: −3.53M USDOperating income, FY2025: −1.04M USDOperating income, FY2026: −1.87M USDNet income, FY2022: −3.19M USDNet income, FY2023: −21.14M USDNet income, FY2024: −4.23M USDNet income, FY2025: 10.19M USDNet income, FY2026: −1.25M USDFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 164.39M USD. Revenue FY2023 148.81M USD. Revenue FY2024 154.54M USD. Revenue FY2025 119.97M USD. Revenue FY2026 132.16M USD. Operating income FY2022 −2.69M USD. Operating income FY2023 −20.93M USD. Operating income FY2024 −3.53M USD. Operating income FY2025 −1.04M USD. Operating income FY2026 −1.87M USD. Net income FY2022 −3.19M USD. Net income FY2023 −21.14M USD. Net income FY2024 −4.23M USD. Net income FY2025 10.19M USD. Net income FY2026 −1.25M USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Revenue132.16M USD119.97M USD154.54M USD148.81M USD164.39M USD
Cost of goods sold127.41M USD116.13M USD123.43M USD114.53M USD127.87M USD
Gross profit4.75M USD3.84M USD31.11M USD34.28M USD36.52M USD
Selling, general, and administrative6.62M USD4.87M USD34.64M USD55.21M USD39.06M USD
Operating expenses6.62M USD4.87M USD34.64M USD55.21M USD39.21M USD
Interest income455.06K USD92.83K USD516.64K USD883.91K USD401.92K USD
Interest expense67.07K USD—13.6K USD65.85K USD262.22K USD
Depreciation and amortization363.69K USD6.02M USD5.38M USD718K USD1.26M USD
Operating income−1.87M USD−1.04M USD−3.53M USD−20.93M USD−2.69M USD
Net income−1.25M USD10.19M USD−4.23M USD−21.14M USD−3.19M USD

Company facts updated Aug 24, 2026.

RDGT peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research RDGT

research.disclaimer